{"created":"2021-03-01T06:28:46.723257+00:00","id":23512,"links":{},"metadata":{"_buckets":{"deposit":"600ea325-6cb6-4fab-b014-200f4a98d14e"},"_deposit":{"id":"23512","owners":[],"pid":{"revision_id":0,"type":"depid","value":"23512"},"status":"published"},"_oai":{"id":"oai:niigata-u.repo.nii.ac.jp:00023512"},"item_7_alternative_title_1":{"attribute_name":"\u305d\u306e\u4ed6\u306e\u30bf\u30a4\u30c8\u30eb","attribute_value_mlt":[{"subitem_alternative_title":"The Fundamental Studies on Natural Killer (NK) Assay and the Clinical Investigation NK Activity in Various Liver Diseases"}]},"item_7_biblio_info_6":{"attribute_name":"\u66f8\u8a8c\u60c5\u5831","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"1988-04","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"4","bibliographicPageEnd":"228","bibliographicPageStart":"220","bibliographicVolumeNumber":"102","bibliographic_titles":[{"bibliographic_title":"\u65b0\u6f5f\u533b\u5b66\u4f1a\u96d1\u8a8c"},{"bibliographic_title":"\u65b0\u6f5f\u533b\u5b66\u4f1a\u96d1\u8a8c","bibliographic_titleLang":"en"}]}]},"item_7_description_4":{"attribute_name":"\u6284\u9332","attribute_value_mlt":[{"subitem_description":"The methodology of NK assay was investigated using K562 cell line as target cells and NK activity of peripheral blood lymphocytes (PBL) obtained from patients with various liver diseases was measured. The susceptibility of K562 cells to NK cell depended on their cell cycle phases, Therefore, it was suggested that NK activity of the same healthy donors should be measured simultaneously in each assay. The NK activity of PBC, as well as LC, was significantly lower than that of other liver diseases. Any suppressive factors against NK activity, however, were not detected in sera from PBC. Serial change of NK activity of 11 HBsAg-positive patients treated with interferon (IFN) was investigated. The augmented NK activity was observed only in the first and second week during IFN treatment and it returned to previous level after the fourth week. Patients with HCC who showed lower NK activity had poorer life prognosis than those who possessed normal NK activity.","subitem_description_type":"Abstract"}]},"item_7_full_name_3":{"attribute_name":"\u8457\u8005\u5225\u540d","attribute_value_mlt":[{"nameIdentifiers":[{"nameIdentifier":"141469","nameIdentifierScheme":"WEKO"}],"names":[{"name":"Yoshida, Toshiaki"}]}]},"item_7_publisher_7":{"attribute_name":"\u51fa\u7248\u8005","attribute_value_mlt":[{"subitem_publisher":"\u65b0\u6f5f\u533b\u5b66\u4f1a"}]},"item_7_select_19":{"attribute_name":"\u8457\u8005\u7248\u30d5\u30e9\u30b0","attribute_value_mlt":[{"subitem_select_item":"publisher"}]},"item_7_source_id_11":{"attribute_name":"\u66f8\u8a8c\u30ec\u30b3\u30fc\u30c9ID","attribute_value_mlt":[{"subitem_source_identifier":"AN00182415","subitem_source_identifier_type":"NCID"}]},"item_7_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"00290440","subitem_source_identifier_type":"ISSN"}]},"item_creator":{"attribute_name":"\u8457\u8005","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"\u5409\u7530, \u4fca\u660e"}],"nameIdentifiers":[{"nameIdentifier":"141468","nameIdentifierScheme":"WEKO"}]}]},"item_files":{"attribute_name":"\u30d5\u30a1\u30a4\u30eb\u60c5\u5831","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2019-08-19"}],"displaytype":"detail","filename":"102(4)_220-228.pdf","filesize":[{"value":"2.0 MB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"102(4)_220-228.pdf","url":"https://niigata-u.repo.nii.ac.jp/record/23512/files/102(4)_220-228.pdf"},"version_id":"20156970-1e91-40b6-b2f2-a9e59a99ba44"}]},"item_keyword":{"attribute_name":"\u30ad\u30fc\u30ef\u30fc\u30c9","attribute_value_mlt":[{"subitem_subject":"NK Activity","subitem_subject_scheme":"Other"},{"subitem_subject":"K562 Cell","subitem_subject_scheme":"Other"},{"subitem_subject":"Liver Disease","subitem_subject_scheme":"Other"},{"subitem_subject":"Interferon Therapy","subitem_subject_scheme":"Other"},{"subitem_subject":"NK \u6d3b\u6027","subitem_subject_scheme":"Other"},{"subitem_subject":"K562 \u7d30\u80de","subitem_subject_scheme":"Other"},{"subitem_subject":"\u809d\u75be\u60a3","subitem_subject_scheme":"Other"},{"subitem_subject":"\u30a4\u30f3\u30bf\u30fc\u30d5\u30a7\u30ed\u30f3\u7642\u6cd5","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"\u8a00\u8a9e","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"\u8cc7\u6e90\u30bf\u30a4\u30d7","attribute_value_mlt":[{"resourcetype":"departmental bulletin paper","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"\u5404\u7a2e\u809d\u75be\u60a3\u306b\u304a\u3051\u308b NK \u6d3b\u6027\u306e\u52d5\u5411\u3068 NK \u6d3b\u6027\u6e2c\u5b9a\u306b\u95a2\u3059\u308b\u57fa\u790e\u7684\u691c\u8a0e","item_titles":{"attribute_name":"\u30bf\u30a4\u30c8\u30eb","attribute_value_mlt":[{"subitem_title":"\u5404\u7a2e\u809d\u75be\u60a3\u306b\u304a\u3051\u308b NK \u6d3b\u6027\u306e\u52d5\u5411\u3068 NK \u6d3b\u6027\u6e2c\u5b9a\u306b\u95a2\u3059\u308b\u57fa\u790e\u7684\u691c\u8a0e"},{"subitem_title":"\u5404\u7a2e\u809d\u75be\u60a3\u306b\u304a\u3051\u308b NK \u6d3b\u6027\u306e\u52d5\u5411\u3068 NK \u6d3b\u6027\u6e2c\u5b9a\u306b\u95a2\u3059\u308b\u57fa\u790e\u7684\u691c\u8a0e","subitem_title_language":"en"}]},"item_type_id":"7","owner":"1","path":["453/456","471/537/538/1223"],"pubdate":{"attribute_name":"\u516c\u958b\u65e5","attribute_value":"2016-04-05"},"publish_date":"2016-04-05","publish_status":"0","recid":"23512","relation_version_is_last":true,"title":["\u5404\u7a2e\u809d\u75be\u60a3\u306b\u304a\u3051\u308b NK \u6d3b\u6027\u306e\u52d5\u5411\u3068 NK \u6d3b\u6027\u6e2c\u5b9a\u306b\u95a2\u3059\u308b\u57fa\u790e\u7684\u691c\u8a0e"],"weko_creator_id":"1","weko_shared_id":null},"updated":"2021-03-01T12:53:39.430470+00:00"}